Cargando…

Editorial: Harnessing chemotherapy resistance and development of novel therapeutic strategies for acute leukemia with KMT2A (MLL)-gene rearrangements

Detalles Bibliográficos
Autores principales:	Esposito, Maria Teresa, Hagström-Andersson, Anna, Stam, Ronald W., Bortoluzzi, Stefania
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393731/ https://www.ncbi.nlm.nih.gov/pubmed/36003510 http://dx.doi.org/10.3389/fphar.2022.977741

Ejemplares similares

Drug Repurposing for Targeting Acute Leukemia With KMT2A (MLL)—Gene Rearrangements
por: Tsakaneli, Alexia, et al.
Publicado: (2021)

Novel Diagnostic and Therapeutic Options for KMT2A-Rearranged Acute Leukemias
por: Lopes, Bruno A., et al.
Publicado: (2022)

Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience
por: Richard-Carpentier, Guillaume, et al.
Publicado: (2021)

Tyrosine kinases in KMT2A/MLL-rearranged acute leukemias as potential therapeutic targets to overcome cancer drug resistance
por: Uckun, Fatih M., et al.
Publicado: (2022)

Novel Compounds Synergize With Venetoclax to Target KMT2A-Rearranged Pediatric Acute Myeloid Leukemia
por: Tregnago, Claudia, et al.
Publicado: (2022)

Identification of Genes Transcriptionally Responsive to the Loss of MLL Fusions in MLL-Rearranged Acute Lymphoblastic Leukemia
por: van der Linden, Marieke H., et al.
Publicado: (2015)

MLL2/KMT2D and MLL3/KMT2C expression correlates with disease progression and response to imatinib mesylate in chronic myeloid leukemia
por: Rabello, Doralina do Amaral, et al.
Publicado: (2018)

MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations
por: Kerstjens, Mark, et al.
Publicado: (2016)

Preclinical Evaluation of Carfilzomib for Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia
por: Cheung, Laurence C., et al.
Publicado: (2021)

The Histone Deacetylase Inhibitor I1 Induces Differentiation of Acute Leukemia Cells With MLL Gene Rearrangements via Epigenetic Modification
por: Yao, Jingfang, et al.
Publicado: (2022)

Irinotecan Induces Disease Remission in Xenograft Mouse Models of Pediatric MLL-Rearranged Acute Lymphoblastic Leukemia
por: Kerstjens, Mark, et al.
Publicado: (2021)

The Impact of PI3-kinase/RAS Pathway Cooperating Mutations in the Evolution of KMT2A-rearranged Leukemia
por: Esposito, Maria Teresa
Publicado: (2019)

RNA binding proteins in MLL-rearranged leukemia
por: Tran, Tiffany M., et al.
Publicado: (2022)

Discovery of fusion circular RNAs in leukemia with KMT2A::AFF1 rearrangements by the new software CircFusion
por: Dal Molin, Anna, et al.
Publicado: (2022)

MLL-Rearranged Leukemias—An Update on Science and Clinical Approaches
por: Winters, Amanda C., et al.
Publicado: (2017)

MLL rearrangements in pediatric acute lymphoblastic and myeloblastic leukemias: MLL specific and lineage specific signatures
por: Zangrando, Andrea, et al.
Publicado: (2009)

The developmental stage of the hematopoietic niche regulates lineage in MLL-rearranged leukemia
por: Rowe, R. Grant, et al.
Publicado: (2019)

Development Refractoriness of MLL-Rearranged Human B Cell Acute Leukemias to Reprogramming into Pluripotency
por: Muñoz-López, Alvaro, et al.
Publicado: (2016)

Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia
por: Feng, Zizhen, et al.
Publicado: (2016)

Decitabine mildly attenuates MLL‐rearranged acute lymphoblastic leukemia in vivo, and represents a poor chemo‐sensitizer
por: Schneider, Pauline, et al.
Publicado: (2020)

The landscape of somatic mutations in Infant MLL rearranged acute lymphoblastic leukemias
por: Andersson, Anna K, et al.
Publicado: (2015)

CRISPR-Cas9 Library Screening Identifies Novel Molecular Vulnerabilities in KMT2A-Rearranged Acute Lymphoblastic Leukemia
por: Schneider, Pauline, et al.
Publicado: (2023)

De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia
por: Hyrenius-Wittsten, Axel, et al.
Publicado: (2018)

Replication stress in MLL-rearrangements
por: Milyavsky, Michael, et al.
Publicado: (2015)

P479: TREATMENT IS SHAPING CLONAL EVOLUTION AND RESISTANCE PATTERNS IN MURINE KMT2A-REARRANGED LEUKEMIA WITH SUBCLONAL FLT3N676K
por: Falqués-Costa, Ton, et al.
Publicado: (2023)

Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements
por: Issa, Ghayas C., et al.
Publicado: (2021)

PB1799: KMT2A-REARRANGED PEDIATRIC ACUTE MYELOID LEUKEMIA
por: Zerkalenkova, E., et al.
Publicado: (2022)

Updates in KMT2A Gene Rearrangement in Pediatric Acute Lymphoblastic Leukemia
por: Górecki, Mateusz, et al.
Publicado: (2023)

Rationale for targeting BCL6 in MLL-rearranged acute lymphoblastic leukemia
por: Hurtz, Christian, et al.
Publicado: (2019)

Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia
por: Brzezinka, Krzysztof, et al.
Publicado: (2019)

DOT1L Inhibition Sensitizes MLL-Rearranged AML to Chemotherapy
por: Liu, Wei, et al.
Publicado: (2014)

A Fibrinogen Alpha Fragment Mitigates Chemotherapy-Induced MLL Rearrangements
por: Eberle, Julia, et al.
Publicado: (2021)

NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia
por: Lopez-Millan, Belen, et al.
Publicado: (2019)

Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia
por: Schneider, Pauline, et al.
Publicado: (2023)

KMT2A-CBL rearrangements in acute leukemias: clinical characteristics and genetic breakpoints
por: Bataller, Alex, et al.
Publicado: (2021)

Erratum: Replication stress in MLL-rearrangements
por: Milyavsky, Michael, et al.
Publicado: (2016)

MLL leukemia-associated rearrangements in peripheral blood lymphocytes from healthy individuals
por: Brassesco, María Sol, et al.
Publicado: (2009)

ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia
por: Germano, Giuseppe, et al.
Publicado: (2017)

Rewiring the Epigenetic Networks in MLL-Rearranged Leukemias: Epigenetic Dysregulation and Pharmacological Interventions
por: Chan, Anthony K. N., et al.
Publicado: (2019)

Perturbation of Methionine/S-adenosylmethionine Metabolism as a Novel Vulnerability in MLL Rearranged Leukemia
por: Barve, Aditya, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pqe4nlsre42cin2miu626nup3d